Literature DB >> 26298709

Growth Inhibition Accompanied by MOB1 Upregulation in Human Acute Lymphoid Leukemia Cells by 3-Deazaneplanocin A.

Jianzhen Shen1, Junnan Su, Dansen Wu, Feng Zhang, Haiying Fu, Huarong Zhou, Meihong Xu.   

Abstract

Our purpose was to investigate the effect of 3-deazaneplanocin A (DZNep) on human T-cell acute lymphoid leukemia (T-ALL) cells, and to explore the underlying molecular mechanisms. The human T-ALL cell line Molt4 was treated with DZNep, and cell proliferation was examined. The expression of Mps one binder kinase activator 1 gene (MOB1) mRNA and protein was determined by RT-PCR and Western blotting, respectively. The histone modification effect of DZNep on the lysine 9 of histone 3 associated with MOB1 promoters was examined with chromatin immunoprecipitation and quantitative PCR, and CpG methylation in MOB1 promoters was detected by bisulfite sequencing PCR. DZNep treatment inhibited the growth of Molt4 cells. The expressions of MOB1 genes were upregulated by DZNep treatment, and histone methylations in their promoters were significantly reduced. The results indicate that DZNep is a promising therapeutic compound for the treatment of human T-ALL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26298709     DOI: 10.1007/s10528-015-9688-7

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  5 in total

1.  miR-664a-3p functions as an oncogene by targeting Hippo pathway in the development of gastric cancer.

Authors:  Lu Wang; Bowen Li; Lu Zhang; Qing Li; Zhongyuan He; Xuan Zhang; Xiaoxu Huang; Zhipeng Xu; Yiwen Xia; Qiang Zhang; Qiang Li; Jianghao Xu; Guangli Sun; Zekuan Xu
Journal:  Cell Prolif       Date:  2019-03-18       Impact factor: 6.831

2.  HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia.

Authors:  Aida Vitkevičienė; Giedrė Skiauterytė; Andrius Žučenka; Mindaugas Stoškus; Eglė Gineikienė; Veronika Borutinskaitė; Laimonas Griškevičius; Rūta Navakauskienė
Journal:  J Oncol       Date:  2019-07-18       Impact factor: 4.375

Review 3.  MOB (Mps one Binder) Proteins in the Hippo Pathway and Cancer.

Authors:  Ramazan Gundogdu; Alexander Hergovich
Journal:  Cells       Date:  2019-06-10       Impact factor: 6.600

Review 4.  EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.

Authors:  Boheng Li; Wee-Joo Chng
Journal:  J Hematol Oncol       Date:  2019-11-21       Impact factor: 17.388

5.  Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer.

Authors:  Abdullah Saleh Al-Wajeeh; Salizawati Muhamad Salhimi; Majed Ahmed Al-Mansoub; Imran Abdul Khalid; Thomas Michael Harvey; Aishah Latiff; Mohd Nazri Ismail
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.